What's new? Log in Free sign up

Filing search / Intellia Therapeutics, Inc. / "Litigation"

Search information

Intellia Therapeutics, Inc.

Companies

"Litigation"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

171 results

Newest first Best match first

NTLA Intellia Therapeutics, Inc.

defaults by or is in litigation with the proposed assignee or subtenant; (7) the use of the Premises by the proposed assignee or subtenant will violate any

27 Feb 25

4:03pm

NTLA Intellia Therapeutics, Inc.

substantial litigation expense, would be a substantial diversion of management and other employee resources from our business and may impact our reputation … the subject of recent litigation. As a result, the ultimate impact, implementation, and meaning of the BPCIA is subject to significant uncertainty

27 Feb 25

4:03pm

NTLA Intellia Therapeutics, Inc.

agreements. Significant information about a partner or other third party. Significant disputes or litigation (including threatened). Governmental

27 Feb 25

4:03pm

NTLA Intellia Therapeutics, Inc.

Provision may impose additional litigation costs on stockholders in pursuing claims covered by the Delaware Forum Provision, particularly

27 Feb 25

4:03pm

NTLA Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act

Intellia Therapeutics Announces Anticipated 2025 Milestones and Pipeline priorities result in NTLA-3001 discontinuation and select, research-focused investment

Intellia Therapeutics Announces Anticipated 2025 Milestones and Pipeline priorities result in NTLA-3001 discontinuation and select, research-focused investment

Regulation FD Disclosure

Regulation FD Disclosure

Quarterly report

7 Nov 24

4:05pm

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Regulation FD Disclosure

ktky ttaf0gy382

Regulation FD Disclosure

hep89iioch9kgeqii

Quarterly report

8 Aug 24

4:06pm

mk2r52v8o3xej3 q6d

Quarterly report

8 Aug 24

4:06pm

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Announces CFO Transition

yxs9t89 z0uo0aesxx

Intellia Therapeutics Announces CFO Transition

Intellia Therapeutics Names Brian Goff to its Board of Directors

9rleogs6mhouhlg

Quarterly report

9 May 24

4:25pm

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.